Cambium Bio Ltd - Asset Resilience Ratio

Latest as of June 2023: 0.00%

Cambium Bio Ltd (CMB) has an Asset Resilience Ratio of 0.00% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

AU$0.00

≈ $0.00 USD Cash + Short-term Investments

Total Assets

AU$2.48 Million

≈ $1.76 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2013–2023)

This chart shows how Cambium Bio Ltd's Asset Resilience Ratio has changed over time. Check how strategically is Cambium Bio Ltd's equity deployed to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Cambium Bio Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Cambium Bio Ltd.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	AU$0.00	0%
Short-term Investments	AU$0.00	0%
Total Liquid Assets	AU$0.00	0.00%

Asset Resilience Insights

Limited Liquidity: Cambium Bio Ltd maintains only 0.00% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company maintains a balanced mix of cash and short-term investments.

Cambium Bio Ltd Industry Peers by Asset Resilience Ratio

Compare Cambium Bio Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Shanghai Allist Pharmaceuticals Co. Ltd. A SHG:688578	Biotechnology	21.11%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Sk Biopharmaceuticals Co Ltd KO:326030	Biotechnology	0.14%
Tango Therapeutics Inc NASDAQ:TNGX	Biotechnology	57.90%
TELIX Pharmaceuticals Ltd AU:TLX	Biotechnology	32.29%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
Hangzhou Biotest Biotech Co Ltd SHG:688767	Biotechnology	0.56%
Theravance Biopharma Inc F:0TB	Biotechnology	37.29%

Annual Asset Resilience Ratio for Cambium Bio Ltd (2013–2023)

The table below shows the annual Asset Resilience Ratio data for Cambium Bio Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2023-06-30	0.00%	AU$0.00 ≈ $0.00	AU$2.48 Million ≈ $1.76 Million	--
2022-06-30	2.71%	AU$69.27K ≈ $49.02K	AU$2.55 Million ≈ $1.81 Million	-3.99pp
2021-06-30	6.70%	AU$570.23K ≈ $403.47K	AU$8.51 Million ≈ $6.02 Million	-5.21pp
2020-06-30	11.91%	AU$570.23K ≈ $403.47K	AU$4.79 Million ≈ $3.39 Million	-11.55pp
2019-06-30	23.45%	AU$596.16K ≈ $421.82K	AU$2.54 Million ≈ $1.80 Million	--
2017-06-30	0.00%	AU$0.00 ≈ $0.00	AU$9.16 Million ≈ $6.48 Million	--
2016-06-30	0.00%	AU$0.00 ≈ $0.00	AU$5.93 Million ≈ $4.20 Million	--
2014-06-30	1.25%	AU$127.75K ≈ $90.39K	AU$10.26 Million ≈ $7.26 Million	-1.81pp
2013-06-30	3.06%	AU$122.93K ≈ $86.98K	AU$4.02 Million ≈ $2.85 Million	--

pp = percentage points

About Cambium Bio Ltd

AU:CMB Australia Biotechnology

Market Cap

$7.93 Million

AU$11.21 Million AUD

Market Cap Rank

#27607 Global

#1371 in Australia

Share Price

AU$0.41

Change (1 day)

-4.65%

52-Week Range

AU$0.35 - AU$0.60

All Time High

AU$22.97